CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B

anti-CD122 monoclonal antibodyPositive
AI Analysis

Summary

Argenx announced its acquisition of Forte Biosciences for $2.2 billion in an all-cash deal at $77 per share, gaining an anti-CD122 monoclonal antibody candidate in development for autoimmune diseases.

Importance:7/10
Sentiment:
0.60
M&Aacquisitionautoimmunemonoclonal antibodycash deal
Related Companies

Read the original article

Published by Endpoints News on July 27, 2026 10:46 AM

Read Original